129 related articles for article (PubMed ID: 12387050)
1. [Repaglinide (NN-623)].
Matsuda M; Kaku K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():555-8. PubMed ID: 12387050
[No Abstract] [Full Text] [Related]
2. [Structures and mechanisms for non SU insulin secretagogues].
Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
[No Abstract] [Full Text] [Related]
3. [Repaglinide (NN-623)].
Kaku K
Nihon Rinsho; 1997 Nov; 55 Suppl():180-5. PubMed ID: 9434464
[No Abstract] [Full Text] [Related]
4. Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide.
Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
Eur J Pharmacol; 1998 May; 348(2-3):265-70. PubMed ID: 9652342
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide for type 2 diabetes mellitus.
Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
[No Abstract] [Full Text] [Related]
6. [A rapid- and short-acting insulinotropic agent KAD-1229].
Komatsu H; Ohnota H; Koizumi T; Satoh F
Nihon Rinsho; 1997 Nov; 55 Suppl():171-9. PubMed ID: 9434463
[No Abstract] [Full Text] [Related]
7. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of a new class of insulin secretagogues.
Malaisse WJ
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S140-3. PubMed ID: 10522840
[TBL] [Abstract][Full Text] [Related]
9. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
Cozma LS; Luzio SD; Dunseath GJ; Langendorg KW; Pieber T; Owens DR
Diabetes Care; 2002 Aug; 25(8):1271-6. PubMed ID: 12145220
[TBL] [Abstract][Full Text] [Related]
11. [Sulfonylurea drugs for type 2 diabetes].
Toyota T
Nihon Rinsho; 2002 Sep; 60 Suppl 9():339-45. PubMed ID: 12387015
[No Abstract] [Full Text] [Related]
12. Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
Cozma LS; Luzio SD; Dunseath GJ; Underwood PM; Owens DR
Diabetes Care; 2005 May; 28(5):1001-7. PubMed ID: 15855557
[TBL] [Abstract][Full Text] [Related]
13. Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia.
Aldhahi W; Armstrong J; Bouche C; Carr RD; Moses A; Goldfine AB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4553-7. PubMed ID: 15356061
[TBL] [Abstract][Full Text] [Related]
14. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.
Stephan D; Winkler M; Kühner P; Russ U; Quast U
Diabetologia; 2006 Sep; 49(9):2039-48. PubMed ID: 16865362
[TBL] [Abstract][Full Text] [Related]
15. Effect of repaglinide upon nutrient metabolism, biosynthetic activity, cationic fluxes and insulin release in rat pancreatic islets.
Louchami K; Jijakli H; Sener A; Malaisse WJ
Res Commun Mol Pathol Pharmacol; 1998 Feb; 99(2):155-68. PubMed ID: 9583090
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide.
Balfour JA; Faulds D
Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
[TBL] [Abstract][Full Text] [Related]
17. Repaglinide at a cellular level.
Krogsgaard Thomsen M; Bokvist K; Høy M; Buschard K; Holst JJ; Lindström P; Gromada J
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):15-8. PubMed ID: 12702003
[TBL] [Abstract][Full Text] [Related]
18. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
Jain S; Saraf S
J Diabetes; 2009 Mar; 1(1):29-35. PubMed ID: 20923517
[TBL] [Abstract][Full Text] [Related]
19. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies.
Malaisse WJ
Eur J Clin Invest; 1999 Jun; 29 Suppl 2():21-9. PubMed ID: 10383607
[TBL] [Abstract][Full Text] [Related]
20. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
Rutten GE
Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
